The present study is a single‐center prospective randomized study with the purposes of investigating the effect of spironolactone combined with RFA on the plasma AngII and ALD levels and the left atrium size in patients with AF and evaluating the relationship between this combination therapy and the success rate of AF treatment, so as to provide further clinical therapeutic investigation on increasing the success rate of AF treatment through the use of RFA procedures. This evidence concerns the gene AGT and atrial fibrillation.